Insider Selling: Neuronetics, Inc. (NASDAQ:STIM) CFO Sells 17,307 Shares of Stock

Neuronetics, Inc. (NASDAQ:STIM) CFO Stephen Furlong sold 17,307 shares of the stock in a transaction on Friday, February 14th. The stock was sold at an average price of $4.11, for a total value of $71,131.77. Following the completion of the transaction, the chief financial officer now owns 454,420 shares of the company’s stock, valued at $1,867,666.20. The trade was a 3.67 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

Stephen Furlong also recently made the following trade(s):

• On Wednesday, February 12th, Stephen Furlong sold 10,845 shares of Neuronetics stock. The shares were sold at an average price of $3.83, for a total value of $41,536.35.
• On Monday, February 10th, Stephen Furlong sold 14,836 shares of Neuronetics stock. The shares were sold at an average price of $3.28, for a total value of $48,662.08.

Neuronetics Price Performance

Shares of STIM stock traded up $0.64 during mid-day trading on Tuesday, reaching $5.00. The stock had a trading volume of 3,620,915 shares, compared to its average volume of 1,700,355. Neuronetics, Inc. has a 12-month low of $0.52 and a 12-month high of $5.07. The company has a market cap of $151.75 million, a P/E ratio of -4.07 and a beta of 2.17. The business has a 50-day simple moving average of $2.27 and a 200 day simple moving average of $1.43. The company has a current ratio of 3.16, a quick ratio of 2.87 and a debt-to-equity ratio of 4.90.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the company. Balyasny Asset Management L.P. increased its position in shares of Neuronetics by 29.5% in the fourth quarter. Balyasny Asset Management L.P. now owns 1,481,771 shares of the company’s stock valued at $2,386,000 after buying an additional 337,539 shares in the last quarter. Geode Capital Management LLC boosted its stake in shares of Neuronetics by 2.8% during the fourth quarter. Geode Capital Management LLC now owns 314,076 shares of the company’s stock valued at $506,000 after acquiring an additional 8,466 shares during the last quarter. HighTower Advisors LLC boosted its stake in shares of Neuronetics by 55.5% during the third quarter. HighTower Advisors LLC now owns 245,982 shares of the company’s stock valued at $187,000 after acquiring an additional 87,816 shares during the last quarter. GSA Capital Partners LLP boosted its stake in shares of Neuronetics by 64.5% during the third quarter. GSA Capital Partners LLP now owns 78,642 shares of the company’s stock valued at $60,000 after acquiring an additional 30,837 shares during the last quarter. Finally, Landscape Capital Management L.L.C. acquired a new stake in shares of Neuronetics during the third quarter valued at $53,000. Hedge funds and other institutional investors own 53.59% of the company’s stock.

Neuronetics Company Profile

Neuronetics, Inc, a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder.